Protease inhibitor-induced diabetic complications : incidence, management and prevention

Protease inhibitors (PIs) have become a crucial element in the treatment of patients infected with HIV. However, the widespread use of PI therapy has also been associated with a number of metabolic adverse effects, including fat redistribution and hyperglycaemia. The objective of this review is a di...

Full description

Saved in:
Bibliographic Details
Published in:Drug safety 2005-01, Vol.28 (3), p.209-226
Main Authors: Lien, Lillian F, Feinglos, Mark N
Format: Article
Language:English
Subjects:
Diabetes Complications - chemically induced
Diabetes Complications - epidemiology
Diabetes Complications - prevention & control
Drug Therapy
Human immunodeficiency virus
Humans
Hyperglycemia - complications
Hyperglycemia - epidemiology
Hyperglycemia - prevention & control
Protease Inhibitors - adverse effects
Protease Inhibitors - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protease inhibitors (PIs) have become a crucial element in the treatment of patients infected with HIV. However, the widespread use of PI therapy has also been associated with a number of metabolic adverse effects, including fat redistribution and hyperglycaemia. The objective of this review is a discussion of the incidence, pathophysiology, management and prevention of PI-associated hyperglycaemia. Initial case reports have been followed by large cross-sectional and cohort studies, which demonstrate that the incidence of PI-induced impaired glucose tolerance, as well as frank diabetes mellitus, is significant and demands attention. Investigations into the pathophysiology behind PI-associated hyperglycaemia have identified an underlying problem of insulin resistance that is presumably caused by both direct PI-induced mechanisms and lipotoxicity. Given this, clinical trials have explored the use of various classes of oral hypoglycaemic agents in the management of PI-induced diabetic complications, and the use of insulin therapy must be considered as well. Newer PI agents are also under development, with the hope of reducing metabolic adverse effects. In the meantime, prevention, in the form of dietary modification, regular physical activity and periodic screening for impaired glucose tolerance, must receive heightened attention in the care plan of patients receiving long-term PI therapy.
ISSN:0114-5916
DOI:10.2165/00002018-200528030-00003